connectbiopharm.com (CNTB) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Connect Biopharma maintains financial stability by licensing asset rights to industry behemoths, which offsets liquidity deficits. The model is based on developing therapies for dermatological pathologies that guarantee multi-year demand. The EV/EBITDA valuation chart shows 0.00. Additionally, Connect Biopharma is developing strategic alliances with global immunology centers for the joint synthesis of antibodies against intestinal and skin inflammation.
connectbiopharm.com - analytical breakdowns and key metrics (CNTB)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Connect Biopharma|CNTB - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Connect Biopharma Holdings Limited|CNTB - Company Cumulative Debt|Debts to Book Capitalization CNTB|CNTB - Company Long-Term Liabilities|Company Short-Term Debt Connect Biopharma|Quick Liquidity connectbiopharm.com
- business earnings and investment ratios data:
CNTB - Company Profit|Expected Profit Connect Biopharma|CNTB - Price to Earnings Multiple|Forward P/E Multiple Connect Biopharma Holdings Limited|CNTB - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple CNTB|CNTB - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Connect Biopharma|CNTB - Earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months connectbiopharm.com|CNTB - Earnings per share increase in current year|Earnings growth forecast for next year Connect Biopharma
Initial company analysis:Connect Pharma CNTB
The stability of Connect Biopharma (CNTB) depends on the success of clinical trials and external financing in the absence of a regular operating cash flow. Under these conditions, the EV/EBITDA multiple chart correlates total capital and debt with earnings before depreciation and amortization, allowing investors to assess the asset's degree of overheating and the risks of a valuation drawdown given the lack of mature commercial products.
Competitors of Connect Biopharma (CNTB)
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|Vera Pharma - EV/EBITDA Multiple|Dianthus Corp (DNTH) - Enterprise Value to EBITDA Ratio|Pharvaris N.V. (PHVS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA AbCellera (ABCL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tourmaline Bio|Enterprise Value to Operating Income Before Depreciation PGEN (Precigen Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pharming (PHAR)|Nektar Corp - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple UPB (Upstream Bio Inc)|zenasbio.com (ZBIO) - Company Value to EBITDA|Immunome - EV/EBITDA Multiple|Gossamer Bio Inc (GOSS) - Enterprise Value to EBITDA Ratio|KALV (KalVista Pharmaceuticals Inc) - Enterprise Value to EBITDA Ratio|SEPN: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio PVLA|SVRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple RIGL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANAB (AnaptysBio Inc)|EV/EBITDA Multiple ATXS (Astria Pharma)|Total Company Value to Operating Income Before Depreciation Ratio enGene Corp (ENGN)|RAPT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Aerovate Therapeutics Inc|Aclaris Therapeutics, Inc. (ACRS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio KYTX (Kyverna Therapeutics Inc.)|TLSA (Tiziana Life Sciences PLC) - EV/EBITDA Multiple|CABA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple VTYX|EV/EBITDA Multiple theratech.com (THTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avalo Therapeutics AVTX|Business Value to Operating Income Before Depreciation ELDN|AGEN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Climb Bio, Inc (CLYM) - Enterprise Value to EBITDA Ratio|ZURA: EV/EBITDA Multiple|atyrpharma.com (ATYR) - EV/EBITDA Multiple|ADAG (Adagene Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Ikena Oncology, Inc. (IMA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Shattuck Labs, Inc. (STTK)|equilliumbio.com - Enterprise Value to Operating Income Before Depreciation|Immunic - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ATRA (Atara Biotherapeutics, Inc.)|InflaRx GmbH - EV/EBITDA Multiple|XFOR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|adicetbio.com (ACET) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio CELU (Celularity)|INMB (INmune Bio, Inc.) - EV/EBITDA Multiple|BRNS: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple KZR|EV/EBITDA Multiple SAB Biotherapeutics Inc. (SABS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Akari Therapeutics plc AKTX|Business Value to Operating Income Before Depreciation ENLV|QTTB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|geovax.com (GOVX) - Enterprise Value to EBITDA Ratio|EDSA: EV/EBITDA Multiple|iBio Inc (IBIO) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CARM|XTLB: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLT|Total Company Value to Operating Income Before Depreciation Ratio hcwbiologics.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptevo Therapeutics Inc. APVO|AIM - Enterprise Value to EBITDA Ratio|ADTX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GRI Bio Corporation (GRI) - Enterprise Value to EBITDA Ratio|XRTX (XORTX Therapeutics Inc.) - Enterprise Value to EBITDA Ratio|reshapelifesciences.com (HIND) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Revelation Biosciences, Inc.|Enterprise Value to Operating Income Before Depreciation INDP (Indaptus Therapeutics Inc)|EV/EBITDA Multiple SCNI|CALI - Company Value to EBITDA|EV/EBITDA Multiple AFMD (Affimed N.V.)|ALLK - Enterprise Value to EBITDA Ratio|HOOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA IGM Biosciences, Inc.|iTeos (ITOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation OCEA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC Biopharm|Enterprise Value to Operating Income Before Depreciation THRD (thirdharmonicbio.com)
